(Alliance News) - Horizon Discovery Group PLC, which designs and engineers genetically modified cells for medical research and clinical applications, on Wednesday said that it has added two new sample formats to its cell-based OncoSpan reference standards for use in the development and validation of workflows for cancer diagnostic assays.
The company's OncoSpan range now includes formalin-fixed paraffin-embedded and cell-free DNA formats for mimicking solid tumors and liquid biopsy samples, respectively, in addition to its genomic DNA format.
"These cell-line derived reference standards closely mimic patient samples and offer an unlimited and reproducible resource to help ensure consistency during the establishment and validation of diagnostic assays," the company said.
Shares in Horizon Discovery were flat at 105.00 pence each in London on Wednesday afternoon.
By Tapan Panchal; tapanpanchal@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
